Inquiry Basket
Loading ......
The pathogen that causes COVID-19 (Coronavirus Disease 2019), SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), is a member of the Coronaviridae family of viruses. This enveloped virus has a positive-sense single-stranded RNA genome and measures between 60 and 140 nm in diameter. Spike protein (S protein), membrane protein (M protein), envelope protein (E protein), nucleocapsid protein (N protein), accessory proteins (ORF3a, ORF6, etc.), and structural proteins (like membrane protein, M protein, envelope protein, and N protein) are all encoded in the approximately 30-kb long SARS-CoV-2 genome. Since the spike protein directly interacts to the ACE2 receptor on host cells, it facilitates viral entrance into cells and is therefore a prime target for vaccine development. S1 and S2 are the two subunits that make up the S protein. The S1 subunit contains the receptor-binding domain (RBD), responsible for recognizing and binding to the ACE2 receptor, while the S2 subunit mediates the fusion of the viral membrane with the host cell membrane.
Figure 1. Diagram of the SARS-CoV-2 Structure.
(Source: Awadasseid A, et al. 2021)
Through the usage of the TMPRSS2 enzyme to cleave the S protein, SARS-CoV-2 attaches itself to the ACE2 receptor on the surface of the host cell. This process facilitates the fusion of the viral and host cell membranes and ultimately releases the virus's RNA genome into the host cell. Multiple non-structural proteins that are translated from the viral RNA come together to form a replication complex that is used for transcription and RNA replication. Within the host cell, new virus particles are created and assembled before being discharged extracellularly through exocytosis to infect more cells.
The host immune system detects and reacts to the viral invasion during infection. An innate immune response, which includes the generation of interferons and other inflammatory factors, is triggered by SARS-CoV-2 infection. In an effort to stop the spread of viruses, these variables stimulate immune cells like natural killer cells, dendritic cells, and macrophages. The adaptive immune response is then triggered, with T cells killing infected cells directly and B cells producing particular antibodies to neutralize the virus. A cytokine storm and an exaggerated inflammatory response are common in severe COVID-19 instances, which can result in multiple organ failure and acute respiratory distress syndrome (ARDS).
Figure 2. Immune Activation Mechanism of mRNA-LNP Vaccines
(Source: Al Fayez N, et al. 2023)
The COVID-19 pandemic was caused by SARS-CoV-2, which was initially discovered in Wuhan, China, towards the end of 2019. It soon spread throughout the world. Around the world, scientists and pharmaceutical companies quickly launched efforts to create vaccines in response to this public health disaster. Emergency use authorization was granted to two COVID-19 mRNA vaccines less than a year after the studies began.
In contrast to conventional vaccines, mRNA vaccines are prized for their quick creation, adaptable manufacture, and simplicity in large-scale production. Messenger RNA (mRNA) serves as the antigen-coding vector in mRNA vaccinations. A particular antigen gene's mRNA is synthesized in vitro, then placed into lipid nanoparticles (LNPs) to be injected into the body. Once within the body, the mRNA enters cells and translates into the antigen protein, which triggers an immune response. Vaccines against newly developing virus strains can be quickly designed and produced thanks to this technological platform.
At now, a number of SARS-CoV-2 mRNA vaccines, such as Moderna's mRNA-1273 and Pfizer/BioNTech's BNT162b2, have been authorized for emergency use. With widespread worldwide distribution, these vaccinations have dramatically decreased COVID-19 infection rates and severity, having shown excellent efficacy in clinical trials.
To address stability issues, scientists have extensively modified the mRNA structure to significantly enhance its stability and translation efficiency. Specifically, two American scientists, Katalin Karikó and Drew Weissman, utilized nucleotide modifications (such as 1-methyl-pseudouridine) to allow synthetic mRNA to evade the body's innate immune recognition system, significantly reducing the immune response and inflammation triggered by mRNA in the body, while enhancing its stability and translation efficiency. This innovative contribution earned them the 2023 Nobel Prize in Physiology or Medicine, revolutionizing our understanding of in vivo mRNA design and delivery, laying the foundation for effective mRNA vaccines.
One core aspect of mRNA vaccines is the design and synthesis of mRNA. Initially considered unstable and prone to degradation by extracellular RNases, mRNA is synthesized via reverse transcription to create a cDNA template, followed by in vitro transcription. To improve mRNA stability and translation efficiency, scientists have introduced multiple optimizations, such as using modified nucleotides (e.g., ψ-uridine), optimizing the 5' and 3' untranslated regions (UTRs), and adding a poly(A) tail at the ends. For instance, modifications like 1-methyl-pseudouridine and 5-methoxyuridine alter mRNA's structure, making it less recognizable by the host immune system, thereby reducing innate immune activation, enhancing stability, and minimizing side effects. Moreover, altering the secondary structure of mRNA lengthens its half-life and raises its resistance to nucleases, increasing protein expression levels. In addition to acting as a translation initiation signal that promotes ribosome binding and the start of protein synthesis, the 5' cap shields mRNA from destruction. By means of certain protein interactions, the poly(A) tail facilitates translation initiation and shields mRNA from 3' exonuclease destruction.
Another core aspect of mRNA vaccines is the optimization of delivery vectors. Direct injection of mRNA into the body faces challenges such as rapid degradation and low cellular uptake efficiency due to RNA's high molecular weight, hydrophilicity, and negative charge, which hinder its membrane penetration. Lipid nanoparticles (LNPs), composed of multiple components like ionizable cationic lipids, cholesterol, helper phospholipids, and PEG-lipids, are the most prominent and widely used RNA vaccine delivery system. The proportions and qualities of these components influence the size, surface charge, and stability of LNPs. LNPs' lipid bilayer structure protects mRNA against destruction by both extracellular and intracellular RNases. Furthermore, LNPs' nanoscale size and charge allow for efficient cellular uptake via endocytosis, with ionizable cationic lipids encouraging endosomal escape and mRNA release into the cytoplasm for translation.
Figure 3. Steps and Stages of the mRNA Vaccine Manufacturing Process.
(Source: Gote V, et al. 2023)
As the pandemic persists, SARS-CoV-2 has undergone various mutations, some of which have increased transmissibility, pathogenicity, and immune evasion. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), posing challenges to existing vaccine efficacy.
Although mRNA vaccines can be quickly designed and produced to address variants, practical application still faces several challenges. For instance, stringent storage and transportation requirements necessitate extremely low temperatures. Some populations, such as the elderly and immunocompromised, exhibit weaker immune responses post-vaccination. Long-term protection and booster shot needs require further study. Additionally, rapid variant spread may lead to reinfections among vaccinated individuals, though typically with milder symptoms, necessitating ongoing evaluation of vaccine efficacy against different variants.
SARS-CoV-2 mRNA vaccines have played a crucial role in combating the COVID-19 pandemic, showcasing the immense potential of modern vaccine technology. However, continuous virus mutation and the complex global pandemic situation necessitate addressing several issues to further enhance clinical application efficacy. Improvements in vaccine formulations and production processes are needed to boost mRNA and LNP stability and immunogenicity. Evaluating vaccine effectiveness in different populations, particularly the elderly, immunocompromised, and children, is essential. Monitoring variant emergence and spread will allow timely vaccine updates to counter new threats. Through ongoing optimization and improvement, we aim to effectively control the COVID-19 pandemic and address other potential viral threats in the future.
We are pleased to see the contributions made by you and your team toward further optimizing SARS-CoV-2 mRNA vaccines. Creative Diagnostics offers a range of high-quality SARS-CoV-2 antigens, antibodies, and ELISA kits to support your experiments. Please visit our website to add these products to your cart, ensuring they are safely and quickly delivered to your laboratory doorstep.
Reference
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| SARS-CoV-2 | DEIA2020 | SARS-CoV-2 Antigen ELISA Kit | 96T | Human | Quantitative | Serum | Inquiry |
| DEIAP015-18 | Human SARS-CoV-2 (Covid-19) Spike Protein S2 Antigen ELISA Kit | 96T | Human | Quantitative | Human serum and plasma and cell culture supernatant | Inquiry | |
| DEIASL020Q | Human Anti-SARS-CoV2(N) IgM ELISA Kit | 96T | Human | Quantitative | Serum, plasma and other biological fluids | Inquiry | |
| DEIASL617 | Mouse anti-SARS-COV-2 Spike RBD IgA ELISA Kit | 96T | Mouse | Quantitative | serum, plasma, tissue homogenates and other biological fluids | Inquiry | |
| DEIASL615 | SARS-CoV-2 Neutralizing Antibody Titer ELISA Kit | 96T | quantitative | serum | Inquiry | ||
| DEIA-NS2307-112 | COVID-19 nucleoprotein ELISA Kit | 96T | Universal | Quantitative | serum, plasma, tissue homogenates and other biological fluids. | Inquiry | |
| DEIA-LL122 | Human COVID-19 Neutralizing Antibody ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids | Inquiry | |
| DEIA-LL243 | Mouse Anti-2019 nCoV(S) IgM ELISA Kit | 96T | Mouse | Quantitative | Serum, plasma, tissue homogenates and other biological fluids | Inquiry | |
| SARS-CoV-2 NP | DEIASL017 | SARS-CoV-2 N ELISA Kit | 96T | Human | Quantitative | Serum, plasma | Inquiry |
| DEIA-NS2307-28 | COVID-19 Spike Protein Accquant ELISA Kit | 96T | Human | Quantitative | serum, plasma, tissue homogenates and other biological fluids. | Inquiry | |
| SARS-CoV-2 Spike glycoprotein | DEIASL018 | SARS-CoV-2 Spike glycoprotein ELISA Kit | 96T | Quantitative | Cell culture supernates, plasma | Inquiry | |
| DEIASL411 | SARS-CoV-2 Spike RBD ELISA Kit | 96T | Quantitative | Cell culture supernates, plasma | Inquiry |
Loading ......
